Hamilton Lane Inc Stock Price, News & Analysis

Hamilton Lane (HLNE) has released its 2025 Market Overview, providing a comprehensive analysis of private markets based on data from over 58,000 funds across 57 vintage years. The report highlights both opportunities and challenges in the private markets landscape.

Key investment recommendations include focusing on credit, infrastructure, and secondaries, maintaining exposure to venture and growth sectors (particularly AI), and targeting U.S. markets over other geographies for the next 4-5 years. The report emphasizes strong opportunities in co-investments and equity sectors where selective positioning is possible.

While short-term performance shows infrastructure and real estate performing well and private credit remaining stable, private equity has experienced recent underperformance. However, long-term fundamentals remain robust, with private credit outperforming public markets for 23 consecutive years and infrastructure maintaining outperformance for 12 years.

The report predicts significant growth in evergreen structures, projecting faster growth than public markets over the next five years, with institutional investors increasing their presence and fees likely to decline.

Hamilton Lane (Nasdaq: HLNE) has launched the Hamilton Lane Private Secondary Fund (HLPSF), a new evergreen investment vehicle registered under the Investment Company Act of 1940. The fund targets U.S. accredited investors and qualified high-net-worth individuals, offering access to the firm's secondary investment platform.

Key features include:

• Quarterly liquidity potential
• Low investment minimums of $25K
• Immediate access to mature private equity investments
• Focus on partially to fully funded secondary investments

The fund aims to provide favorable risk-adjusted returns through a diversified portfolio across sponsors, strategies, industries, vintages, and geographies. It is part of Hamilton Lane's broader secondaries platform, which manages $24.1 billion in assets as of December 31, 2024, and extends the firm's $9+ billion Evergreen Platform.

Cosette Pharmaceuticals has announced a definitive agreement to acquire Mayne Pharma Group for approximately USD $430 Million at AUD$7.40 per share. The transaction is expected to close in Q2 2025.

The acquisition will transform Cosette into a leading player in women's health and dermatology in the U.S., combining Cosette's 350+ strong team with Mayne Pharma's 480+ workforce. The merged entity will operate two FDA-approved manufacturing facilities in Lincolnton, North Carolina and Salisbury, South Australia.

Post-acquisition, Cosette will market 12 patent-protected products including notable brands such as VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® and RHOFADE®. The transaction has received approval from both companies' Boards of Directors, with Mayne Pharma's Board unanimously recommending shareholders vote in favor.

73 Strings has secured a $55 million Series B funding round led by Growth Equity at Goldman Sachs Alternatives, with participation from Blackstone Innovations Investments, Golub Capital, Hamilton Lane (HLNE), and Broadhaven Ventures. The company, which provides AI-powered data extraction, monitoring, and valuation solutions for the $17.6 Trillion AUM Alternative Asset Management space, will use the funds to accelerate product development and innovation.

The platform serves clients managing nearly $10 trillion in assets, enabling faster and more frequent valuations with enhanced transparency. The company plans to expand its capabilities through: building smarter systems with LLMs, implementing benchmarking & predictive analytics, introducing portfolio simulation features, and launching advanced dashboards specifically designed for private capital data.

PSG, a growth equity firm focused on software and technology-enabled services, has announced the closure of two funds totaling $8 billion in capital commitments. The firm's sixth North American flagship fund, PSG VI, closed at $6 billion, exceeding its predecessor fund of $4.7 billion. Additionally, PSG closed a $2 billion continuation fund, PSG Sequel, backed by major institutional investors including CPP Investments, GIC, StepStone, and Hamilton Lane.

PSG Sequel will maintain stakes in six portfolio companies: Arcoro, LivTech, Nextlane, Semarchy, Singlewire Software, and Transit Technologies. The firm, founded in 2014, has grown to manage over $28 billion in assets, with 269 professionals including 160 investment professionals. PSG has executed 75 realization events and expanded globally with offices in Boston, London, Kansas City, Paris, Madrid, and Tel Aviv. The firm has invested in 19 AI-driven companies and continues to leverage AI across its portfolio.

Hamilton Lane (Nasdaq: HLNE) has announced the pricing of a public offering of 1,572,536 shares of Class A common stock, with expected gross proceeds of approximately $252 million. The offering, which includes shares from both Hamilton Lane and a selling stockholder, is expected to close on February 12, 2025.

The company plans to use its portion of the proceeds to settle cash exchanges of membership units in Hamilton Lane Advisors, L.L.C. held by certain members. Hamilton Lane will not receive any proceeds from the selling stockholder's share sale. Morgan Stanley is serving as the book-running manager and underwriter for the offering, which is being conducted under an effective shelf registration statement filed with the SEC.

Hamilton Lane (Nasdaq: HLNE) has announced an underwritten public offering of 1,572,536 shares of Class A common stock, to be sold by both the company and a selling stockholder. The private markets asset management firm plans to use its portion of the proceeds to settle cash exchanges of membership units in Hamilton Lane Advisors held by certain members. The company will not receive any proceeds from the selling stockholder's share sale.

Morgan Stanley is serving as the book-running manager and underwriter for the offering. The offering is being conducted under an effective shelf registration statement (Registration No. 333-283233) filed with the SEC.

Cosette Pharmaceuticals has appointed Vincent Colicchio as Senior Vice President of Operations, effective February 3, 2025. Colicchio brings over 35 years of experience in pharmaceutical manufacturing and supply chain operations. Most recently, he served as Vice President of Supply Chain and External Manufacturing at Dr. Reddy's Laboratories, where he managed operations across North America and oversaw a network of more than 45 CMOs and CPOs.

In his previous role, Colicchio played a key role in acquiring and integrating Mayne Pharma's generics portfolio. His experience includes senior leadership positions at Amneal Pharmaceuticals, G&W Laboratories, GlaxoSmithKline, UCB Pharma, and Wyeth. At Cosette, he will lead manufacturing, global supply chain, and operational strategy to support the company's growth and transformation initiatives.

Hamilton Lane (Nasdaq: HLNE) announced the final close of its inaugural Venture Access Fund (VAF), raising $615.3 million in commitments, exceeding its $500 million target by 23%. The Fund targets top-performing, oversubscribed venture funds and companies, combining primary and secondary transactions to accelerate capital returns and mitigate the J-curve.

The fundraise attracted diverse global investors, including public and corporate pension funds, financial institutions, Taft-Hartley plans, family offices, and foundations. The Fund leverages Hamilton Lane's nearly 30-year venture investing experience and $117 billion in AUM and AUA across venture and growth equity.

The firm sees compelling opportunities in the current VC market, driven by AI and disruptive technologies, along with robust secondary market opportunities as companies stay private longer.